Single H<sub>2</sub>S molecule mediates three-stage antibacterial and immunomodulatory effects in dendritic mesoporous organosilica (DMOS-4MPBA) nanoplatform.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41447787.
- Also identified by DOI 10.1016/j.biomaterials.2025.123941.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bacterial infections and inflammatory diseases pose a severe global health threat, driven by antibiotic resistance and dysregulated immune responses. To overcome these challenges, we designed redox-responsive dendritic mesoporous organosilica nanoparticles (DMOS-4MPBA) that utilize a single gaseous molecule - hydrogen sulfide (H<sub>2</sub>S) - as a multifunctional therapeutic agent. DMOS-4MPBA releases H<sub>2</sub>S selectively within infected microenvironments through glutathione-responsive cleavage of polysulfide bonds. The released H<sub>2</sub>S concurrently executes three therapeutic mechanisms: disrupting bacterial energy metabolism and membrane integrity, suppressing quorum sensing to inhibit biofilm formation, and promoting immune regulation via macrophage polarization toward the pro-repair M2 phenotype. Both in vitro and in vivo experiments demonstrate strong antibacterial effects, efficient biofilm disruption, and accelerated wound healing, without compromising biosafety. By integrating antibacterial, anti-biofilm, and immunomodulatory capacities into a single H<sub>2</sub>S-releasing platform, we provide a innovative and potent strategy for treating drug-resistant infections and inflammatory diseases.
Medical subject headings
- Anti-Bacterial Agents
- Hydrogen Sulfide
- Nanoparticles
- Organosilicon Compounds
- Immunologic Factors